Baricitinib versus dexamethasone for adults hospitalised with COVID-19 (ACTT-4): a randomised, double-blind, double placebo-controlled trial, The Lancet Respiratory Medicine

RCT (n=1,010) found a similar rate of mechanical ventilation free survival at day 29 for baricitinib vs dexamethasone (+remdesivir) for patients hospitalised with COVID-19 (87.0% vs 87.6%), though there were fewer adverse events with baricitinib (30% vs 37% of patients p=0.014).
Source: Current Awareness Service for Health (CASH) - Category: Consumer Health News Source Type: news